Webster Brian Daniel 4
4 · KESTRA MEDICAL TECHNOLOGIES, LTD. · Filed Jul 17, 2026
Research Summary
AI-generated summary of this filing
Kestra Medical (KMTS) CEO Brian Webster Receives 176,470 Shares, Sells 15,000
What Happened
Brian Daniel Webster, President and Chief Executive Officer of Kestra Medical Technologies, had 176,470 shares issued to him on July 15, 2026 upon vesting of performance-based RSUs (PSUs) granted July 17, 2025 (acquired at $0.00). On the same date he disposed of 15,000 shares in three open-market/private-sale transactions for aggregate proceeds of approximately $336,610 (11,216 shares at a weighted avg $22.01 ≈ $246,870; 784 shares at $22.63 ≈ $17,745; 3,000 shares at $24.00 ≈ $71,995).
Key Details
- Transaction date: July 15, 2026; Form 4 filed July 17, 2026 (timely).
- Award: 176,470 shares from PSUs (100% vested); acquisition price reported $0.00.
- Sales: 15,000 total shares sold for combined proceeds ≈ $336,610 (see per-lot weighted averages above). Reported sale price ranges: $21.45–$22.44, $22.45–$23.00, and $23.49–$24.10 (weighted averages reported in filing).
- Sales were reported as occurring pursuant to a Rule 10b5-1 trading plan adopted Sept 29, 2025.
- Shares owned after the transactions are not specified in the provided excerpt.
- Transaction codes in filing: A = Award/Acquisition (PSUs); S = Sale.
Context
The 176,470 shares represent performance-based RSUs that vested (compensation), not an open-market purchase. The subsequent sales were executed under a pre-established 10b5-1 plan, which typically indicates pre-arranged transactions rather than opportunistic trading; filings do not state insider motivation. Purchases generally carry stronger positive signaling than routine vesting or pre-planned sales.
Insider Transaction Report
- Award
Common Shares
[F1]2026-07-15+176,470→ 571,937 total - Sale
Common Shares
[F2][F3]2026-07-15$22.01/sh−11,216$246,870→ 560,721 total - Sale
Common Shares
[F2][F4]2026-07-15$22.63/sh−784$17,745→ 559,937 total - Sale
Common Shares
[F2][F5]2026-07-15$24.00/sh−3,000$71,995→ 556,937 total
Footnotes (5)
- [F1]Represents common shares earned with respect to an award of performance-based RSUs ("PSUs") granted on July 17, 2025, as determined based on the Issuer's achievement of specified performance goals. 100% of the PSUs vested on July 15, 2026.
- [F2]The reported transaction occurred pursuant to a Rule 10b5-1 trading plan adopted on September 29, 2025.
- [F3]The price in Column 4 is a weighted average price. The prices at which the reported securities were sold ranged from $21.45 to $22.44. Upon request, the reporting person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, information regarding the number of shares at each price within the range.
- [F4]The price in Column 4 is a weighted average price. The prices at which the reported securities were sold ranged from $22.45 to $23.00. Upon request, the reporting person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, information regarding the number of shares at each price within the range.
- [F5]The price in Column 4 is a weighted average price. The prices at which the reported securities were sold ranged from $23.49 to $24.10. Upon request, the reporting person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, information regarding the number of shares at each price within the range.